泊洛妥珠单抗治疗复发/难治性非霍奇金淋巴瘤患者的概况：关于新出现临床数据的简要报告
Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data.
作者信息
Sawalha Yazeed, Maddocks Kami
机构信息
Department of Internal Medicine, Division of Hematology, Arthur G. James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
出版信息
Onco Targets Ther. 2020 Jun 8;13:5123-5133. doi: 10.2147/OTT.S219449. eCollection 2020.
ABSTRACT
Polatuzumab vedotin is an anti-CD79b antibody conjugated to monomethyl auristatin E that has shown significant clinical activity in follicular and diffuse large B-cell lymphoma (DLBCL) and is currently FDA-approved in combination with bendamustine and rituximab for patients with relapsed/refractory DLBCL. This review article summarizes data from clinical trials of polatuzumab and discusses its current role and future directions in the treatment of patients with B-cell non-Hodgkin lymphoma.
METHODS
We conducted a literature search in PubMed and Google Scholar from inception to January 2020, using the following terms: polatuzumab and CD79. We also reviewed the package insert and available abstracts and posters presented at national and international meetings.
摘要
泊洛妥珠单抗是一种与单甲基奥瑞他汀E偶联的抗CD79b抗体，已在滤泡性和弥漫性大B细胞淋巴瘤（DLBCL）中显示出显著的临床活性，目前已获美国食品药品监督管理局（FDA）批准，可与苯达莫司汀和利妥昔单抗联合用于复发/难治性DLBCL患者。这篇综述文章总结了泊洛妥珠单抗的临床试验数据，并讨论了其在B细胞非霍奇金淋巴瘤患者治疗中的当前作用和未来方向。
方法
我们在PubMed和谷歌学术上进行了从数据库建立到2020年1月的文献检索，使用了以下检索词：泊洛妥珠单抗和CD79。我们还查阅了药品说明书以及在国内和国际会议上展示的可用摘要和海报。
Zotero 插件